Pharmaceutical Drugs Industry Overview

The naloxone spray market consists of sales of naloxone spray by entities (organizations, sole traders, and partnerships) – the product is prefilled with naloxone, and a needle-free device is sprayed into one nostril, and it requires no assembly. It is used for treating opioid emergencies with symptoms such as problems with breathing and severe sleepiness or inability to respond. Naloxone is a non-scheduled prescription drug which belongs to the class of medications called opiate antagonists, and is used to reverse or prevent the effects of opioid narcotic overdose for drugs such as codeine, fentanyl, morphine, and oxycodone. Naloxone comes as a solution (liquid) to spray into the nose and each naloxone nasal spray contains a single dose of naloxone and should be used only once. The main types of dosages involved in the naloxone spray include 2 mg/actuation and 4 mg actuation. 2 mg/actuation sprays naloxone is equivalent to 1.8 mg naloxone and is used for emergency medication of known or suspected opioid overdose, as demonstrated by respiratory and/or central nervous system depression. The 2 mg dose is licensed for use in opioid-dependent individuals who are at risk of severe opioid withdrawal and who live in an environment with a low risk of accidental or purposeful opioid exposure by household contacts. Naloxone sprays are available in various distribution channels such as hospitals, clinics, retail pharmacies, online pharmacies, others. The global naloxone spray market is expected to grow from $285.09 million in 2020 to $351.39 million in 2021 at a compound annual growth rate (CAGR) of 23.3%. The change in growth trend of the naloxone spray market is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The naloxone spray market is expected to reach $785.35 million in 2025 at a CAGR of 22.3%. The increasing prevalence of opioid overdoses is contributing to the growth of the naloxone spray market. Opioids include medicines such as morphine, fentanyl, and tramadol that are used for the treatment of pain. However, due to their pharmacological effects, their non-medical use, prolonged use, misuse, and use without medical supervision can lead to opioid dependence and can cause breathing difficulties, or even lead to death or other health problems. For instance, in 2019, opioids were involved in 49,860 overdose deaths (70.6% of all drug overdose deaths). According to WHO, as of 2020, more than 70% of deaths are related to opioids, and out of these 30% of deaths are caused by overdose. As a part of emergency medical treatment, naloxone nasal spray is used to reverse the life-threatening effects of opiate or opioids overdose. Therefore, the increasing prevalence of opioid overdoses drives the growth of the naloxone spray market. The increase in product approvals is shaping the naloxone spray market. Major companies manufacturing naloxone sprays are focused on new product approvals to broaden their product portfolios and expand their naloxone spray business. For instance, in April 2021, the US Food and Drug Administration (FDA) approved Hikma Pharmaceuticals KLOXXADOTM (naloxone hydrochloride) nasal spray 8 mg for the immediate treatment of recognized or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, in adult and pediatric patients. KLOXXADOTM provides an important new treatment to address the opioid epidemic and contains twice as much naloxone per spray as Narcan Nasal Spray 4mg in a ready-to-use nasal spray to reverse the effects of opioid overdose. In August 2019, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company acquired Insys Therapeutics Inc’s naloxone, epinephrine nasal sprays for an undisclosed amount. The acquisition enhances Hikma Pharmaceuticals PLC's nasal spray capabilities, resulting in a comprehensive platform that can be used for both internal and external programs. Insys Therapeutics Inc is a US-based company that manufactures naloxone, epinephrine nasal sprays. Major players in the naloxone spray market are Emergent BioSolutions, Pfizer, Teva Pharmaceutical Industries Ltd., Opiant Pharmaceuticals, Hikma Pharmaceuticals, Nasus Pharma, Amphastar Pharmaceuticals, Indivior PLC, Samarth Pharma Pvt. Ltd., Troikaa Pharmaceuticals Ltd., and Neon Laboratories Limited. North America was the largest region in the naloxone spray market in 2020. The regions covered in the naloxone spray market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the naloxone spray market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global naloxone spray market is segmented - 1) By Dosage: 2 mg/Actuation, 4 mg/Actuation 2) By Distribution Channel: Hospitals, Clinics, Retail Pharmacies, Online Pharmacies, Others

The nanomedicine market consists of sales of nanotechnology-based applications in medicines by entities (organizations, sole-trader, and partnerships) that are engaged in utilizing nanomaterials for the enhanced diagnosis and treatment of various health issues. Nanomedicine is a branch of medicine that applies nanotechnology knowledge and tools for the prevention and treatment of disease. They are nanoscale materials that are used in diagnosis and treatment procedures in oncology, cardiology, infectious diseases, orthopedics, and other medical areas. Nanomedicine is an important instrument that enables personalized, targeted, and regenerative medicine by delivering improved new drugs, treatments, and implantable devices to clinicians and patients. The main types of nanomedicine are nanoparticles, nanoshells, nanotubes, nanodevices, and others. Nanoparticles are a type of ultrafine particles usually between 1 and 100 nanometers in diameter used in making medicine and drugs. The different forms of modality include diagnostics, treatments, and are used in clinical oncology, infectious diseases, clinical cardiology, orthopedics, others. The global nanomedicine market is expected to grow from $190.83 billion in 2020 to $221.12 billion in 2021 at a compound annual growth rate (CAGR) of 15.9%. The change in growth trend of the nanomedicine market is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The nanomedicine market is expected to reach $361.44 billion in 2025 at a CAGR of 13.1%. The rising burden of complex and chronic diseases across the globe is expected to contribute to the growth of the nanomedicine market in the forecast period. Nanomedicine is increasingly being used in treating chronic diseases including cardiovascular disorders, diabetes, cancer, dementia, and others where it helps in the fast metabolism of drugs in the body. According to the international federation of Alzheimer's associations, Alzheimer's Disease International, more than 50 million people are suffering from dementia globally, and this is projected to double every 20 years, reaching 80 million by 2030 and 152 million by 2050. In 2020, the total cancer burden in the world increased to 19.3 million new cases and is predicted to rise to 28.4 million new cancer cases in 2040. This increasing burden of chronic diseases is expected to propel the demand for effective therapeutics treatment based on nanomedicine, thus driving the market. 4D Nanomedicine is a key trend gaining popularity in the nanomedicine market. 4D nanomedicine is used in medical procedures for safer treatment with nanoparticles. 4D nanomedicine is made with biodegradable and biocompatible nanoalloys that do not accumulate in the body, thus limiting the side effects. 4D nanomedicine is accepted as a fundamental development in the treatment and diagnosis of cancer. For instance, in 2020, a research team from The Department of Chemical Sciences, University of Padua investigated and confirmed the effectiveness of inorganic 4D nanoparticles in the biomedical field. 4D nanomedicine offers several advantages to the biomedical field including reduced side effects in a living organism, minimal environmental impact, improved quality of care, and spontaneous effect. In November 2019, Bristol-Myers Squibb (BMS), a US-based pharmaceutical company completed the acquisition of Celgene for $74 billion. Under this acquisition, Celgene will be a wholly-owned subsidiary of BMS and Bristol-Myers Squibb plans to expand its range of innovative medicines. Celgene is a US-based biopharmaceutical company that focuses on improving the lives of patients through innovative therapies using nanomedicine and nanotechnology. Major players in the nanomedicine market are Pfizer Inc., Nanotherapeutics Inc., NanoViricides Inc, Arrowhead Research Inc., Celgene Corporation, Bio-Gate AG, Merck AG, Ablynx NV, F. Hoffmann-La Roche AG, Nanospectra Biosciences, GE Healthcare, Gilead Sciences Inc., Novartis AG, Amgen Inc., and Sanofi. North America was the largest region in the nanomedicine market in 2020. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nanomedicine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the nanomedicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global nanomedicine market is segmented - 1) By Type: Nanoparticles, Nanoshells, Nanotubes, Nanodevices, Others 2) By Modality: Diagnostics, Treatments 3) By Application: Clinical Oncology, Infectious Diseases, Clinical Cardiology, Orthopedics, Others

The pegfilgrastim biosimilars market consists of the sales of pegfilgrastim biosimilars and related services offered by the companies that develop and manufacture them. Pegfilgrastim is a version of filgrastim (Neupogen), used to increase the production of infection-fighting white blood cells for the treatment of cancer patients undergoing chemotherapy. Pegfilgrastim biosimilars find their applications in reducing infection for patients undergoing anticancer therapy.

The pegfilgrastim biosimilar market covered in this report is segmented by application into chemotherapy treatment, transplantation, others and by distribution channel into hospital pharmacies, retail pharmacies, mail-order pharmacies.

The global pegfilgrastim biosimilars market is expected to grow from $0.8 billion in 2020 to $0.88 billion in 2021 at a compound annual growth rate (CAGR) of 10%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The pegfilgrastim biosimilars market is expected to reach $1.42 billion in 2025 at a CAGR of 13%.

Government initiatives for the development of biosimilars are expected to drive the pegfilgrastim biosimilars. Governments worldwide are focusing on the development of biosimilars attributing to their cost-effective nature. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, in July 2018 to increase treatment options. The Australian government is committed to the Biosimilar Awareness Initiative and in 2018 they improved their commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription and use of biosimilar medicines. Hence, the government initiatives for the development of biosimilars aids in the increased production and awareness which in turn supported the growth of the pegfilgrastim biosimilars market.

During the historic period the pegfilgrastim biosimilar market was restrained by the low number of drug approvals by the FDA. The market currently only has 4 drugs approved for treatment, thus restraining the growth of the market. This can be attributed to strict standards for manufacturing and high drug efficacy standards set by the regulatory bodies for approval of this therapy, thus increasing the time required for approval and limiting the growth of the market.

Companies in the pegfilgrastim biosimilar market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as academic and research institutions in this market by way of partnerships, in or out licensing deals, this trend has been increasing over the recent years. For instance, in July 2018, Fulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved by the FDA.

In October 2018, Mundipharma, a UK-based company engaged in manufacturing, developing, and commercializing high-quality biosimilars for inflammatory diseases and oncology acquired Cinfa Biotech. Mundipharma acquired all shares of Cinfa, Infarco including Pelmeg (pegfilgrastim, biosimilar). This acquisition is projected to expand Mundipharma's biosimilar product portfolio. Cinfa Biotech was founded in 2013 as a part of Cinfa Group and is a Spanish biotechnology company that focuses on the development of biosimilars.

Major players in the pegfilgrastim biosimilars market are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals, and Fresenius Kabi.

The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pegfilgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global pegfilgrastim biosimilars market is segmented -

1) By Application: Chemotherapy Treatment, Transplantation, Others

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

CAR-T Therapy Market Definition

The chimeric antigen receptor -T therapy market consists of sales of CAR-T therapy products and related services by entities (organizations, sole traders and partnerships) that develop chimeric antigen receptor (CAR) T-cell therapies to treat blood cancers. CAR-T therapy is type of immunotherapy in which T-cells taken from patient’s blood are modified in a laboratory with the addition of a special protein receptor that grants T-cells the power to recognize as well as kill cancer cells easily, along with infusing the same back into that patient. This special protein receptor, known as the chimeric antigen receptor (CAR), attaches to a specific protein on a patient’s cancer cells. The infused cells multiply and prevail in the patient’s body as living drugs. This industry includes establishments that are involved in the research and development to introduce new targeted cell therapies for treating indications related mostly to hematological malignancies. However, some of the pipeline CAR-T therapies are aimed at targeting solid tumors including pancreatic cancer, breast cancer, ovarian cancer, gastric cancer, kidney cancer, brain tumor, and other cancer types.

Central Nervous System Drugs Market Definition

The central nervous system (CNS) drugs market consists of sales of central nervous system drugs and related services by entities (organizations, sole traders and partnerships) that manufacture central nervous system drugs that are used in the treatment of diseases affecting the brain or spinal cord. The CNS drugs include anesthetics, anticonvulsants, antiemetics, antiparkinsonian agents, CNS stimulants, analgesics, and sedatives. Neurological diseases such as Epilepsy, Parkinson and psychological indications such as depression, and dementia are generally treated through these CNS drugs. Nervous system disorders are defined as disorders that affect the brain as well as the nerves found throughout the human body and the spinal cord. Structural, biochemical or electrical abnormalities in the brain, spinal cord or other nerves can result in a range of symptoms. Some of the common clinical indications of such disorders include paralysis, muscle weakness, poor coordination, loss of sensation, seizures, confusion, pain and altered levels of consciousness. These also include mental health conditions such as depression and post-traumatic stress disorder (PTSD). The market for CNS disorder drugs comprises of drugs that work in different ways depending on the type of disease by suppressing or boosting the brain activities.

Vaccines Market Definition

The vaccines market consists of sales of vaccines and related services by entities (organizations, sole traders and partnerships) that produce vaccines to prevent various diseases. Vaccines are biological preparations that stimulate the immune system and prepare it to fight future infections caused by pathogens. They trigger the production of antibodies against pathogens or any foreign matter that enters the body. Vaccines can be administered orally, through injections or by aerosol. Vaccine doses are administered to both children (pediatric vaccines) and adults based on the schedule set for each vaccine. For adults, the vaccines are recommended based on age, health condition, prior vaccinations and occupation. The vaccines market is segmented into anti-infective vaccines; anti-cancer vaccines; and other-vaccines. Only goods and services traded between entities or sold to end consumers are included. Vaccines are preventative medicines which are administered to the general population or to those vulnerable in a population as a precautionary measure to combat a disease, they may include single or multiple doses. Vaccines work by mimicking the infectious bacteria or virus that cause a disease. They energize the body’s immune system to build up a defensive mechanism against the infectious virus or bacteria without causing the disease. Vaccines contain weakened versions of bacteria or virus, and some contain only part of the bacteria or virus. Specific vaccines also contain only the genetic material for a specific protein which directs the body to produce similar type of protein.

The multivitamin capsules and tablets market consists of sales of multivitamin capsules and tablets by entities (organizations, sole traders, and partnerships) that produce multivitamin capsules and tablets which are used to provide vitamins. Multivitamins tablets and capsules are a combination of many different vitamins that are normally found in foods and other natural sources. Multivitamins are used to treat vitamin deficiencies that are caused by illness, pregnancy, poor nutrition, digestive disorders, and other different conditions.

The main types of products include multivitamins tablets and multivitamins capsules. A multivitamin is a pill that people take every day which contains a variety of vitamins and minerals. The different distribution channels include store-based, non-store-based and are used for energy and weight management, general health, bone, and joint health, gastrointestinal health, immunity, cardiac health, diabetes, anti-cancer, and other applications. These capsules and tablets are mainly used by adults, the geriatric population, pregnant women, children, and infants.

The global multivitamin capsules and tablets market is expected to grow from $16.50 billion in 2020 to $18.24 billion in 2021 at a compound annual growth rate (CAGR) of 10.6%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The multivitamin capsules and tablets market is expected to reach $24.80 billion in 2025 at a CAGR of 8%.

Increasing health consciousness among individuals is driving the market for multivitamin capsules and tablets. Multivitamins tablets or capsules are often prescribed by doctors to treat or prevent vitamin deficiency due to poor diet, certain illnesses, or during pregnancy as it contains different vitamins that are normally found in foods and other natural sources. The demand for multivitamins also increased attributing to rising health concerns associated with the COVID-19 pandemic. According to SVC Labs Ltd, a UK-based supplement manufacturer the sales for vitamins, minerals and supplements have increased since the beginning of March 2020 as people are concerned with boosting immune health. The sales of vitamins, minerals, and supplements have experienced growth of approximately 20%-140% since March 2020. Therefore, rising health consciousness is expected to drive the multivitamin capsules and tablets market during the forecast period.

Shifting consumer focus towards flavored gummy vitamins for all ages is shaping the multivitamin capsules and tablets market. Consumers are searching for more convenient and entertaining supplement experiences, which will lead to a move toward flavored gummy vitamins. For instance, in April 2021, Persona Nutrition, a US-based company that provides personalized daily supplement packs launched daily gummy vitamin packs for the entire family. These daily packs are designed to help users achieve specific health goals, such as immune health, focus, relaxation, everyday support, and hair, skin, and nail health. This family pack includes multivitamins to boost muscle and nerve function.

In April 2019, Unilever Limited, a UK-based consumer goods company acquired OLLY Nutrition for an undisclosed amount. This acquisition will complement Unilever’s businesses in beauty & personal care and foods & refreshment. OLLY Nutrition is a US-based company specializing in manufacturing and selling vitamins, minerals, supplements.

Major players in the multivitamin capsules and tablets market are Herbalife Nutrition, Abbott Laboratories, Bayer, Nature's Bounty Co., Bionova Lifesciences, Ayanda GmbH, NutraMarks Inc, American Health Inc, Otsuka Holdings Co. Ltd., Nature's Way Products, Glanbia Plc, Pfizer, Mylan N.V., and Dymatize.

Asia Pacific was the largest region in the multivitamin capsules and tablets market in 2020. North America was the second-largest market in the multivitamin capsules and tablets market. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the multivitamin capsules and tablets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global multivitamin capsules and tablets market is segmented -

1) By Type: Multivitamins Tablets, Multivitamins Capsules

2) By Distribution Channel: Store Based, Non-Store Based

3) By Application: Energy & Weight Management, General Health, Bone & Joint Health, Gastrointestinal Health, Immunity, Cardiac Health, Diabetes, Anti-Cancer, Others

4) By End User: Adults, Geriatric, Pregnant Women, Children, Infants

The precision medicine market consists of sales of precision medicines and related services by entities (organizations, sole traders, and partnerships) that are used to treat diseases by relying on genomics and specific biomarker techniques. It allows doctors or physicians to select a treatment plan or drug therapy based on the patient’s genetic understanding of their disease, environment, and lifestyle. The precision medicine technologies also assist researchers and doctors in developing accurate treatment and prevention strategies for a particular disease that will work on a specific group of people.

The main technologies involved in precision medicine are bioinformatics, big data analytics, drug discovery, gene sequencing, companion diagnostics, and others. Bioinformatics technologies involve the application of computational tools to organize, analyze, understand, visualize and store information associated with biological macromolecules. It is used in oncology, respiratory diseases, central nervous disorders, immunology, genetic diseases, others and is implemented in various sectors such as hospitals and clinics, pharmaceuticals, diagnostic companies, healthcare, and IT firms, among others.

The global precision medicine market is expected to grow from $62.75 billion in 2020 to $72.58 billion in 2021 at a compound annual growth rate (CAGR) of 15.7%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The precision medicine market is expected to reach $118.32 billion in 2025 at a CAGR of 13%.

The rising prevalence of cancer is projected to fuel the growth of the precision medicine market in the coming years. Cancer is one of the main causes of death worldwide, with one out of every five individuals developing cancer at some point in their lives. Precision medicine in cancer entails analyzing DNA from tumors to find mutations or other genetic abnormalities that cause cancer. Physicians may therefore be able to choose a treatment for a specific patient's cancer that best fits, or targets, the tumor DNA alterations. For instance, according to recent predictions from the International Agency for Research on Cancer (IARC), the global cancer burden increased to 19.3 million cases and 10 million cancer deaths in 2020. Therefore, the rising prevalence of cancer drives the growth of the precision medicine market.

The development of novel precision medicine for pancreatic cancer is shaping the precision medicine market. Extensive research is being undertaken on different approaches to develop precision medicines for pancreatic cancer. For instance, in October 2020, Scientists from the University Of Glasgow announced the development of a novel precision medicine approach for treating the damaged DNA in the cancer cells of pancreatic cancer patients. The team used grown cells from the lab and replicas of patients' tumors to find molecular markers, which were used in the prediction and response to several drugs, targeting DNA damage. The researchers tested certain markers using multiple drugs, also developed a strategy that is taken forward into a clinical trial. The trial will help doctors and researchers to predict which patient will respond to one of these drugs, either alone or in combination.

In April 2021, Servier Laboratories, a France-based pharmaceutical company acquired Agios Pharmaceuticals Inc.’s commercial, clinical, and research-stage oncology portfolio for an undisclosed amount. The acquisition of Servier Laboratories is focused on strengthening its commercial presence in the malignant technology market and provides the potential for long-term growth into the solid tumor space. The transaction includes marketed oncology precision medicine in malignant technology, clinical oncology pipeline with multiple early-stage and phase-3 assets. Agios Pharmaceuticals is a US-based company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway.

Major players in the precision medicine market are Qiagen, Novartis AG, Medtronic, AstraZeneca plc., Quest Diagnostics, Thermo Fisher Scientific Inc., Pfizer, Bristol-Myers Squibb, Merck & Co. Inc., Tepnel Pharma Services, Abbott Laboratories, Takeda Pharmaceutical Company Ltd., and Eli Lilly and Company.

North America was the largest region in the precision medicine market in 2020. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the precision medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global precision medicine market is segmented -

1) By Technology: Big Data Analytics, Bioinformatics, Gene Sequencing, Drug Discovery, Companion Diagnostics, Others

2) By Application: Oncology, Respiratory Diseases, Central Nervous System Disorders, Immunology, Genetic Diseases, Others

3) By End-User: Hospitals And Clinics, Pharmaceuticals, Diagnostic Companies, Healthcare And IT Firms, Others